Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01747499 · ClinicalTrials.gov registry record · Phase 1
Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01747499 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 54 participants.
The verdict
NCT01747499, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this phase I/II study is to define the maximum tolerated dose of 5-AzaC and the effect on grade II-IV GvHD when given after matched unrelated donor transplant (MUD).
Interventions
- DRUG Azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2013-04-15 |
| Est. Completion | 2018-12-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01747499
The ClinicalTrials.gov registry entry for NCT01747499 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azacitidine is the first listed.
NCT01747499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01747499 about?
NCT01747499 is a clinical study titled "Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation". The purpose of this phase I/II study is to define the maximum tolerated dose of 5-AzaC and the effect on grade II-IV GvHD when given after matched unrelated donor transplant (MUD).
What is the current status of trial NCT01747499?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2013-04-15. Estimated completion is 2018-12-24.
What interventions are being tested in trial NCT01747499?
The interventions under investigation include: Azacitidine (DRUG).
Who is sponsoring clinical trial NCT01747499?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.